Arrowhead Pharmaceuticals develops RNA interference medicines intended to reduce the production of disease associated proteins. Its research uses delivery technologies designed to bring RNA therapeutics into selected tissues, with programs in cardiometabolic, liver and other serious diseases. The company is headquartered in Pasadena, California, and maintains research operations in Madison, Wisconsin. Arrowhead has both internally developed and partnered programs, so commercial and development rights can vary by medicine. Its investor relations site provides the authoritative current securities information and ongoing company disclosures.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Arrowhead Pharmaceuticals develops RNA interference medicines intended to reduce the production of disease associated proteins. Its research uses delivery technologies designed to bring RNA therapeutics into selected tissues, with programs in cardiometabolic, liver and other serious diseases. The company is headquartered in Pasadena, California, and maintains research operations in Madison, Wisconsin. Arrowhead has both internally developed and partnered programs, so commercial and development rights can vary by medicine. Its investor relations site provides the authoritative current securities information and ongoing company disclosures.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Arrowhead develops RNAi therapeutics using its TRiM platform, which combines RNA triggers, targeting ligands, linkers, and chemical modifications. Liver and extrahepatic programs must be assessed by candidate and indication.
Business, technology & evidence
Arrowhead Pharmaceuticals develops RNA interference medicines intended to reduce the production of disease associated proteins. Its research uses delivery technologies designed to bring RNA therapeutics into selected tissues, with programs in cardiometabolic, liver and other serious diseases. The company is headquartered in Pasadena, California, and maintains research operations in Madison, Wisconsin. Arrowhead has both internally developed and partnered programs, so commercial and development rights can vary by medicine. Its investor relations site provides the authoritative current securities information and ongoing company disclosures.
SecuritiesNasdaq Global Select Market: ARWR
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Arrowhead reported Phase 1/2a interim data involving 21 ARO-DIMER-PA recipients and 10 placebo recipients. Across dose cohorts, mean LDL-C fell 26%–65% and median triglycerides fell 56%–78% from baseline; these were not placebo-adjusted effects. Injection-site erythema occurred in 20 treated participants, and one participant receiving 400 mg experienced Grade 3 syncope. Cardiovascular outcome benefit remains unestablished.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
